Insider · CIK 0001794351
Franklin Stuart Friedman
Files at DCPH (Deciphera Pharmaceuticals, Inc.). First filing Jun 12, 2023, latest Jun 12, 2023.
In brief
Franklin Stuart Friedman files SEC Form 4 as director at DCPH (Deciphera Pharmaceuticals, Inc.). Since Jun 12, 2023, Franklin Stuart Friedman has reported 1 open-market buy worth $139k and 0 open-market sells worth $0, the latest filed on Jun 12, 2023.
A track record needs three past buys with six months of prices behind them; Franklin Stuart Friedman has 0, so none is measured yet.
The newest scored trade: bought $139k of DCPH on Jun 8, 2023, filed Jun 12, 2023, scored 34 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | DCPHbuy Deciphera Pharmaceuticals, Inc. | $139k 10,000 shares | - | - |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | UTender of shares Common Stock | -10,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,269 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,727 | - | - | 0 | Jun 11, 2024 |
| Jan 16, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,727 | $10.58 | $50k | 4,727 | Jan 18, 2024 |
| Jun 21, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 23, 2023 |
| Jun 8, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +10,000 | $13.88 | $139k | 10,000 | Jun 12, 2023 |
| Jan 17, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,269 | $15.30 | $50k | 3,269 | Jan 19, 2023 |
Questions about Franklin Stuart Friedman
Answered from the filings on this page, as of the latest one.
Is Franklin Stuart Friedman buying or selling?
Not in the last 12 months. Franklin Stuart Friedman's latest open-market trade on SEC Form 4 was bought $139k of DCPH on Jun 8, 2023.
How did Franklin Stuart Friedman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Franklin Stuart Friedman has 0.
Where does Franklin Stuart Friedman file Form 4?
Franklin Stuart Friedman has filed Form 4 at DCPH (Deciphera Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.